

Weight Gain and the Risk of Developing Insulin Resistance Syndrome

SUSAN A. EVERSON, PHD, MPH
DEBBIE E. GOLDBERG, MS
SUSAN P. HELMRICH, PHD
TIMO A. LAKKA, MD, PHD

JOHN W. LYNCH, PHD, MPH
GEORGE A. KAPLAN, PHD
JUKKA T. SALONEN, MD, PHD, MSCPH

OBJECTIVE — Obesity and weight gain have been associated independently with hypertension, hyperinsulinemia, and dyslipidemia; however, prior research has not looked at the relation between weight gain from early adulthood to middle age and the development of this cluster of risk factors, known as insulin resistance syndrome.

RESEARCH DESIGN AND METHODS — The association between weight gain over 30 years (defined as the difference between measured weight in middle age and participant recall of their weight at age 20) and the odds of developing insulin resistance syndrome at middle age was examined in a population-based sample of 2,272 eastern Finnish men.

RESULTS — Each 5% increase in weight over the reported weight at age 20 was associated with nearly a 20% greater risk of insulin resistance syndrome by middle age, after adjustment for age and height. Moreover, there was a strong graded association between categories of weight gain and risk of insulin resistance syndrome. Men with weight increases of 10–19%, 20–29%, or $\geq 30\%$ since age 20 were 3.0, 4.7, or 10.6 times more likely to have insulin resistance syndrome, respectively, by middle age, compared with men within 10% of their weight at age 20. Adjustments for age, height, physical activity, smoking, education, and parental history of diabetes did not alter these findings.

CONCLUSIONS — The odds of having developed the hemodynamic and metabolic abnormalities that characterize insulin resistance syndrome by middle adulthood were increasingly higher the greater the weight gain over the preceding 30 years. This study adds to the literature identifying deleterious effects of weight gain from young to middle adulthood.

Diabetes Care 21:1637–1643, 1998

Epidemiological, experimental, and clinical evidence shows that obesity and weight gain are associated with increased risk for cardiovascular diseases (CVDs) and events and type 2 diabetes, and with risk factors for these disorders, including hypertension, dyslipidemia, glucose intolerance, and insulin resistance (1–9). Weight loss may reduce these risk

factors and could delay or prevent the onset of CVD, type 2 diabetes, and other diseases associated with increased weight (3). Weight fluctuates to some degree throughout one's life and is known to increase with age. Mechanisms of weight gain and the amount and duration of increased weight in relation to known risk factors for CVD and type 2 diabetes are less well understood.

Few individuals at risk of CVD or type 2 diabetes have only one risk factor (10). Usually, several hemodynamic and metabolic abnormalities cluster together in an individual. Various combinations of these factors have been referred to as Reaven's syndrome, syndrome X, the deadly quartet, metabolic cardiovascular syndrome, and others (11). Because resistance to insulin-stimulated glucose uptake appears to be a primary mechanism underlying these abnormalities, the currently recommended term is insulin resistance syndrome (11,12). Some definitions of insulin resistance syndrome imply that obesity is an essential component; however, Reaven (13) argues that because all of the elements of insulin resistance syndrome can be seen in nonobese individuals and can develop independently of obesity, obesity should not be included.

There is a direct correspondence between insulin action and relative weight (14), and, as noted, weight gain is associated with incident hypertension and glucose intolerance (1,8,9). However, few studies have specifically investigated the association between increases in weight over time and development of insulin resistance syndrome. Accordingly, we examined the relationship between weight gain from early to middle adulthood and occurrence of insulin resistance syndrome, defined as the co-occurrence of hyperinsulinemia, dyslipidemia, and hypertension, in a population sample of middle-aged eastern Finnish men.

RESEARCH DESIGN AND METHODS

Subjects

Subjects were from the Kuopio Ischemic Heart Disease Risk Factor Study (KIHD), a study designed to investigate unestablished risk factors for ischemic heart disease, carotid atherosclerosis, and related outcomes in a population-based sample of eastern Finnish men (15). Of the 3,433 eligible men aged 42, 48, 54, or 60 years residing in or around the town of Kuopio, 198 were excluded because of death, serious disease, or migration from the area. A total of 2,682 (82.9%) agreed to participate in the study.

From the Department of Epidemiology (S.A.E., J.W.L., G.A.K.), University of Michigan School of Public Health, Ann Arbor, Michigan; the Human Population Laboratory (D.E.G., S.P.H.), Public Health Institute, Berkeley, California; the Research Institute of Public Health (T.A.L., J.T.S.), University of Kuopio; and the Department of Medicine (T.A.L.), Kuopio University Hospital, Kuopio, Finland.

Address correspondence and reprint requests to Susan A. Everson, PhD, MPH, Department of Epidemiology, University of Michigan School of Public Health, 109 S. Observatory St., Ann Arbor, MI 48109-2029. E-mail: severson@umich.edu.

Received for publication 12 January 1998 and accepted in revised form 11 June 1998.

Abbreviations: CVD, cardiovascular disease; dBp, diastolic blood pressure; IHD, ischemic heart disease; KIHD, Kuopio Ischemic Heart Disease Risk Factor Study; sBP, systolic blood pressure; WHR, waist-to-hip ratio.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

Baseline examinations were conducted between March 1984 and December 1989. No significant differences have been found between participants and nonparticipants (16). For this study, men treated for diabetes with insulin ($n = 6$) and those with missing data on weight at age 20, on weight at the baseline examination ($n = 207$), or on any covariates ($n = 197$) were excluded, leaving 2,272 subjects in the analyses.

Assessment of weight and weight gain

Weight. Current weight was measured at the baseline exam using a balance scale. Weight at age 20 was assessed from a self-report questionnaire administered at baseline.

Percent weight gain. Percent weight gain was calculated as weight change (difference in measured baseline weight and recalled weight at age 20) divided by the age 20 weight, multiplied by 100.

BMI. BMI was calculated as weight (kilograms) divided by height (meters) squared.

Waist-to-hip ratio (WHR). WHR at baseline was calculated as the ratio of waist circumference (average of one measure taken after inspiration and one taken after expiration at the midpoint between the lowest rib and the iliac crest) to hip circumference (measured at the level of the trochanter major).

Assessment and definition of insulin resistance syndrome

Venous samples were obtained after fasting and abstinence from smoking for 12 h, abstinence from alcohol for 3 days, and abstinence from analgesics for 7 days. After a 30-min supine rest, blood was drawn without tourniquet, using Terumo Venoject VT-100 PZ vacuum tubes (Terumo, Tokyo). Samples were cooled immediately on ice (4°C). After centrifugation, serum was frozen (-80°C) and stored until assay.

Blood glucose. Blood glucose level was determined from fresh blood samples with the glucose dehydrogenase method after precipitation of the proteins with trichloroacetic acid (Granutest 100; Merck, Darmstadt, Germany).

Serum insulin. Serum insulin level was determined from frozen serum samples with a Novo Biolabin radioimmunoassay kit (Novo Nordisk, Bagsvaerd, Denmark).

Lipids. HDL cholesterol was separated from fresh serum samples using precipitation and ultracentrifugation (17). Cholesterol contents of lipoprotein fractions and serum triglycerides were measured enzymatically (Boehringer Mannheim, Mannheim, Germany).

Systolic blood pressure (sBP) and diastolic blood pressure (dBP). Blood pressure was measured with a random-zero sphygmomanometer (Hawksley, London, U.K.) by a trained observer. Consistent with current guidelines (18), sBP and dBP were each calculated as the average of two measurements, taken at min 5 and 10 of a 10-min seated rest.

Medications. Information on medication for hypertension, diabetes, and other disorders was obtained from a self-administered questionnaire and confirmed during the medical interview. Medications were grouped and coded by a nurse using the Nordic Pharmacopoeia coding system.

Insulin resistance syndrome. Insulin resistance syndrome cases were identified if they met the following criteria at the baseline examination: 1) hypertension, sBP ≥ 160 mmHg or dBP ≥ 95 mmHg (19) or use of antihypertensive medication; 2) hyperinsulinemia, fasting serum insulin ≥ 11.7 mU/l (upper tertile of the baseline distribution of serum insulin); and 3) dyslipidemia, serum HDL cholesterol < 1.0 mmol/l, or serum triglycerides ≥ 2.3 mmol/l (20).

Five additional subjects were classified as cases because they were hypertensive and dyslipidemic and showed evidence of hyperglycemia at baseline, with fasting blood glucose ≥ 6.7 mmol/l (21) or reported history of diabetes controlled by diet or oral medication.

Assessment of baseline covariates

Age. Age at baseline was modeled by dummy-coded variables for ages 48, 54, and 60 years, with age 42 as the referent.

Height. Height was measured at the baseline exam and modeled continuously (centimeters).

Smoking. Cigarette smoking was assessed by self-report. Nonsmokers (people who never smoked) were the reference category, with a dummy-coded variable for former smokers and a continuous variable for current smokers (pack-years).

Physical activity. Physical activity was assessed at baseline by using a 12-month leisure-time history modified from the Minnesota Leisure Time Physical Activity Questionnaire to represent the 16 most common leisure-time physical activities of middle-aged Finnish men and by including self-reported intensity of physical activity (22). For each activity on the questionnaire, subjects reported either not engaging in the activity or the frequency per month over the preceding year, average duration per occa-

sion, and intensity level. Metabolic units were assigned for each activity according to reported intensity. Details on methods of calculation, reliability, and validity of these measures have been described elsewhere (16). Analyses used an intensity-dependent measure of total duration of physical activity that previously predicted type 2 diabetes in this population (23).

Education. Education, assessed as self-reported years of school completed, was modeled continuously.

Parental diabetes. Parental history of diabetes was assessed from self-report and modeled by a dummy-coded variable for each parent's history.

Statistical analysis

The relationship between percentage of gained weight and odds of having insulin resistance syndrome was examined using age- and height-adjusted unconditional logistic regression models. Subsequent models included covariates for age, height, physical activity, smoking, education, and maternal and paternal history of diabetes. Two sets of analyses were performed. Initially, percentage of gained weight was entered into the models continuously. In the second set of analyses, percentage of gained weight was divided into approximate quartiles: $< 10\%$ of weight at age 20 (reference category), 10–19, 20–29, and $\geq 30\%$. Men whose baseline weight was the same or less than their self-reported weight at age 20 ($n = 238$) were included in the first quartile. (Separate analyses with these 238 men as the reference category produced results nearly identical to those reported and did not provide useful information regarding the impact of minimal weight gain [1–15 lb] on insulin resistance syndrome.) Less than 2% of all participants ($n = 44$) lost $\geq 10\%$ of their reported age 20 weight by the baseline exam and thus constituted too small of a group to examine separately. Tests for trend, in odds ratios and other variables, were calculated by comparing adjacent categories of percent weight gain (24). A trend test was interpreted as significant if all comparisons achieved the specified criterion, which in this study was adjusted for three comparisons and set at $P < 0.0167$ (0.05/3).

Additional analyses compared insulin resistance syndrome cases with noncases on subject characteristics, with age adjustment. Significance values were computed using paired t tests or χ^2 tests, as appropriate. Subject characteristics also were examined by the categories of percentage of




Figure 1—Distribution of insulin resistance syndrome and its components among 2,272 men.

gained weight. Analyses were conducted using LOGISTIC and GLM procedures in SAS (SAS Institute, Cary, NC), version 6.12.

RESULTS — Figure 1 presents the distribution of the three components of insulin resistance syndrome. There were 168 men (7.4%) who had hypertension, hyperinsulinemia, and dyslipidemia at baseline, thus meeting the criteria for insulin resistance syndrome. Approximately 55% of participants had one or two components of insulin resistance syndrome, whereas 852 men (37.6%) had none.

Compared with men without insulin resistance syndrome, those with the syndrome were significantly older and heavier, had greater WHR and BMI in middle age, and were more likely to report a positive maternal history of diabetes (Table 1). Additionally, prevalence of obesity (BMI ≥ 28 kg/m²) was significantly higher among men with than among those without insulin resistance syndrome. Participants with and without the insulin resistance syndrome did not differ in self-reported weight at age 20 (68.2 vs. 67.6 kg), although those with the syndrome gained significantly more weight by middle age (31.1 vs. 18.5% of age 20 weight).

Weight gain and odds of having insulin resistance syndrome

Percentage of gained weight from young to

middle adulthood was significantly associated with prevalence of insulin resistance syndrome at baseline. Modeled continuously, percentage of gained weight was associated with an odds ratio of 1.04 (β coefficient, 0.0359; 95% CI 1.04–1.05) for insulin resistance syndrome, after age and height adjustment. In other words, each 5% increase over the reported age 20 weight

was associated with nearly 20% higher odds of having insulin resistance syndrome in middle age. Adjustments for physical activity, smoking, education, and parental history of diabetes did not alter this finding.

With percentage of gained weight modeled categorically, a strong, positive, graded association was observed between categories of weight gain and odds of having insulin resistance syndrome (Table 2). Compared with men who gained <10% of their age 20 weight, those who gained 10–19, 20–29, or $\geq 30\%$ were approximately 3, 4.7, and 10.6 times more likely, respectively, to have insulin resistance syndrome in middle age, after adjusting for age and height. Associations were relatively unchanged after adjustment for physical activity, smoking, education, and parental history of diabetes. The test for trend by comparison of adjacent categories was significant ($P < 0.0167$), indicating significantly increasing risk with increasing weight gain.

Because fasting insulin may be a less reliable marker of insulin sensitivity and thus a less accurate measure of hyperinsulinemia among people with impaired glucose tolerance (25), we also examined the association between weight gain and insulin resistance syndrome while excluding participants whose baseline fasting glucose was ≥ 6.7 mmol/l ($n = 20$) or who reported diabetes controlled by diet or oral medications ($n = 4$). Results were essentially identical to those reported above (data not shown).

Table 1—Baseline subject characteristics of 2,272 men with (cases) and without (noncases) insulin resistance syndrome

Characteristics	Cases	Noncases	P value
<i>n</i>	168	2,104	—
Weight at baseline (kg)	89.1 \pm 0.91	79.7 \pm 0.26	<0.0001
WHR at baseline	0.99 \pm 0.005	0.94 \pm 0.001	<0.0001
Age (years)	54.3 \pm 0.41	52.8 \pm 0.11	<0.0003
Height (cm)	173.1 \pm 0.47	172.9 \pm 0.13	<0.78
BMI at baseline (kg/m ²)	29.7 \pm 0.27	26.6 \pm 0.08	<0.0001
Obesity (%)	63.7	29.3	<0.0001
Physical activity (min/week)	75.2 \pm 10.70	85.3 \pm 3.02	<0.36
Education (years)	9.3 \pm 0.26	8.7 \pm 0.07	<0.02
Smoking status (%)			
Never	20.8	27.1	<0.08
Former	45.2	39.0	<0.11
Current	33.9	33.8	<0.98
Parental history of diabetes (%)			
Mother	27.4	19.0	<0.008
Father	5.4	6.9	<0.45

Data shown are age-adjusted means \pm SEM or prevalence (%). Obesity was defined as BMI ≥ 28 kg/m². P values are from *t* tests or χ^2 tests comparing cases and noncases.

Table 2—Odds ratios and 95% CIs for insulin resistance syndrome among 2,272 men by categories of percent weight gained from age 20 to age at the baseline examination

Percent weight gain	Odds ratio (95% CI)
Model 1	
<10	1.00 (Referent)
10–19	3.08 (1.57–6.06)
20–29	4.69 (2.42–9.09)
≥30	10.61 (5.72–19.68)
Model 2	
<10	1.00 (Referent)
10–19	2.89 (1.46–5.70)
20–29	4.51 (2.32–8.77)
≥30	10.20 (5.46–19.05)

Model 1 was adjusted for age and height; Model 2 was adjusted for age, height, physical activity, smoking, education, and maternal and paternal history of diabetes.

Weight gain and subject characteristics

Table 3 presents age-adjusted means ± SEM or prevalence (%) of subject characteristics across the categories of percentage of gained weight. The proportion of insulin resistance syndrome cases increased from 1.8 to 16.5% from the lowest to the highest weight-gain categories. Not surprisingly, significant trends across categories were noted for weight at middle age and self-reported weight at age 20: men with the most weight

gain were the heaviest in middle age and had the lowest weight at age 20. This group had the correspondingly highest average BMI and WHR in middle age. Trends across weight-gain categories for other characteristics listed in Table 3 were not significant, although the pattern for smoking status is informative. Men with the largest weight gain were more likely to be former smokers (49.8%) than were those whose weight remained relatively stable (30.3%).

Weight gain and individual components of insulin resistance syndrome

To examine the effects of weight gain on individual components of insulin resistance syndrome, we calculated a series of unconditional logistic regression models with percentage of gained weight modeled either continuously or categorically and with hypertension, hyperinsulinemia, or dyslipidemia as the outcomes. Percentage of gained weight from age 20 to middle age was significantly associated with each component of insulin resistance syndrome and most strongly related to hyperinsulinemia. Modeled continuously, the odds ratio for percentage of gained weight was 1.04 (β coefficient, 0.0355; 95% CI 1.03–1.04) for hypertension, 1.02 (β coefficient, 0.0202; 95% CI 1.01–1.03) for dyslipidemia, and 1.07 (β coefficient, 0.0649; 95% CI 1.06–1.08) for hyperinsulinemia, after age and height adjustment. In other words, each

5% increase over reported age 20 weight was associated with a 19% greater chance of becoming hypertensive, an 11% greater chance of becoming dyslipidemic, and a 38% greater chance of being hyperinsulinemic by middle age.

With weight gain modeled categorically, men who had gained 10–19, 20–29 or ≥30% of their age 20 weight were at increasingly greater risk of having hypertension, dyslipidemia, and hyperinsulinemia by middle age, compared with men who had relatively stable weight (Table 4). Adjustments for risk factors did not change the associations.

Weight gain and insulin resistance syndrome by history of ischemic heart disease (IHD)

Metabolic and hemodynamic abnormalities associated with insulin resistance syndrome also underlie CVD (10,13), and it is conceivable that associations between weight gain and occurrence of insulin resistance syndrome could vary according to history of CVD. Thus, we recalculated the logistic regression models separately for participants with and without prevalent IHD at baseline. Participants were considered to have prevalent IHD if they reported a history of angina pectoris or prior myocardial infarction during the baseline medical interview; currently used anti-angina medication; or had positive findings of angina according to the Rose Questionnaire (26).

Table 3—Subject characteristics by category of percent weight gain

	Percent weight gain			
	<10	10–19	20–29	≥30
Cases/n (%)	12/673 (1.8)	31/587 (5.3)	38/486 (7.8)	87/526 (16.5)
Weight at baseline (kg)	71.0 ± 0.36	78.3 ± 0.38	83.0 ± 0.42	92.2 ± 0.40
Weight at age 20 (kg)	70.1 ± 0.28	68.1 ± 0.30	66.7 ± 0.33	64.8 ± 0.032
WHR at baseline	0.91 ± 0.002	0.94 ± 0.003	0.96 ± 0.003	0.99 ± 0.003
Age (years)	52.7 ± 0.20	52.7 ± 0.22	52.8 ± 0.24	53.6 ± 0.23
Height (cm)	172.2 ± 0.23	172.8 ± 0.25	173.3 ± 0.27	173.6 ± 0.26
BMI at baseline (kg/m ²)	23.9 ± 0.10	26.2 ± 0.11	27.6 ± 0.12	30.6 ± 0.11
Physical activity (min/week)	86.3 ± 5.34	91.0 ± 5.71	81.3 ± 6.28	78.0 ± 6.05
Education (years)	8.5 ± 0.13	9.1 ± 0.14	8.8 ± 0.15	8.6 ± 0.15
Smoking status (%)				
Never	29.7	28.6	25.7	21.5
Former	30.3	39.0	41.6	49.8
Current	40.0	32.4	32.7	28.7
Parental history of diabetes (%)				
Maternal	16.8	20.6	20.8	20.9
Paternal	7.3	7.5	6.4	5.7

Data are means ± SEM or prevalence (%). Mean percentage of gained weight across categories was 1.6, 14.9, 24.5, and 42.7%, respectively. Weight at baseline, weight at age 20, WHR at baseline, and BMI at baseline had a Bonferroni-adjusted P for trend ≤0.017.

Table 4—Odds ratios and 95% CIs for hypertension, dyslipidemia, and hyperinsulinemia among 2,272 men by categories of percent weight gained from age 20 to age at the baseline examination

	Percent weight gain			
	<10	10–19	20–29	≥30
Model 1				
Hypertension	1.00 (Referent)	1.98 (1.56–2.53)	2.72 (2.12–3.50)	4.61 (3.59–5.92)
Dyslipidemia	1.00 (Referent)	1.69 (1.26–2.27)	1.92 (1.42–2.60)	2.86 (2.15–3.81)
Hyperinsulinemia	1.00 (Referent)	2.62 (1.94–3.53)	6.40 (4.77–8.60)	14.63 (10.87–19.70)
Model 2				
Hypertension	1.00 (Referent)	1.94 (1.52–2.47)	2.65 (2.06–3.42)	4.36 (3.39–5.62)
Dyslipidemia	1.00 (Referent)	1.74 (1.29–2.34)	2.01 (1.48–2.74)	3.12 (2.33–4.18)
Hyperinsulinemia	1.00 (Referent)	2.53 (1.87–3.42)	6.39 (4.74–8.61)	14.71 (10.87–19.91)

Data are odds ratios (95% CI). Cases: $n = 936$ for hypertension; $n = 501$ for dyslipidemia; $n = 803$ for hyperinsulinemia. Model 1 was adjusted for age and height; Model 2 was adjusted for age, height, physical activity, smoking, education, and maternal and paternal history of diabetes.

Results were essentially unchanged from the full model. There were 102 cases of insulin resistance syndrome among 1,724 men without IHD. After age and height adjustment, men with weight gain of 10–19, 20–29, or $\geq 30\%$ or more had 2.9 (95% CI 1.3–6.7), 4.7 (95% CI 2.1–10.6), and 9.5 (95% CI 4.4–20.5) greater odds of insulin resistance syndrome in middle age, relative to men within 10% of their age 20 weight. Among the 548 men with a history of IHD, there were 66 cases of insulin resistance syndrome. Weight gain was associated with 3.7 (95% CI 1.1–12.0), 4.6 (95% CI 1.4–14.7), and 11.8 (95% CI 4.1–34.1) greater odds of insulin resistance syndrome, respectively, across weight gain categories. Adjustment for risk factors did not affect the associations between weight gain and insulin resistance syndrome in men with or without prevalent IHD.

CONCLUSIONS — This study shows that middle-aged men who gained $>10\%$ of their age 20 weight were significantly more likely to have developed hypertension, hyperinsulinemia, and dyslipidemia, the characteristic clustering of risk factors known as insulin resistance syndrome, over the intervening years, than were men whose weight remained stable. Risk of developing insulin resistance syndrome was increased by nearly 20% for every 5% gain in weight from age 20 to an average age of 53. This increased risk was independent of age, height, physical activity, smoking, education, and parental history of diabetes. To our knowledge, this is the first study to examine the association between weight gain from early to middle adulthood and the occurrence of insulin resistance syndrome.

Information in this study was obtained cross-sectionally; however, a temporal distinction is possible for weight gain because we have data on weight at two time points. Our findings suggest that weight gain preceded the development of insulin resistance syndrome; however, lack of information on insulin levels, blood pressure, triglycerides, and HDL levels of these men at age 20 did not allow us to examine if any characteristics of insulin resistance syndrome were present in young adulthood, before weight gain. Nonetheless, several lines of evidence support the interpretation that the insulin resistance syndrome seen in 7% of our sample occurred after weight gain. Weight gain can lead to hyperinsulinemia and is associated with glucose intolerance and insulin resistance (8,27,28). Similarly, obesity is known to be an insulin-resistant state and is strongly associated with hyperinsulinemia (29,30). Nearly 64% of our cases met the criterion for obesity at baseline (Table 1), whereas obesity was nearly nonexistent among cases ($n = 1$) and noncases ($n = 23$) at age 20. Interestingly, however, more than one third of our cases were not obese, and yet weight gain in adulthood apparently triggered metabolic alterations that contributed to insulin resistance syndrome in these men. The pattern of association between weight gain and insulin resistance syndrome among nonobese men was similar to that found in the entire sample, with increasingly greater weight gain related to increasingly higher odds of insulin resistance syndrome (data not shown). Moreover, in the full sample, post hoc adjustment for baseline WHR, a reliable indicator of abdominal obesity, did not diminish the observed dose-response pattern of associations, which remained significant, although

the point estimates were decreased somewhat (odds ratios: 1.0, 2.0, 2.5, and 4.5 from lowest to highest weight-gain categories, respectively).

Insulin resistance most commonly occurs as a result of increasing weight, lack of exercise, aging, or diseases or drugs that antagonize the actions of insulin (31) and may be strongly influenced by genetic factors (32). We suspect that the weight gain experienced from young to middle adulthood by our subjects contributed to a state of insulin resistance and resulting hyperinsulinemia, hypertension, and dyslipidemia in middle age. That weight gain was more strongly associated with hyperinsulinemia than with hypertension or dyslipidemia (Table 4) is consistent with this interpretation and supports the notion that insulin resistance underlies metabolic and hemodynamic disturbances characteristic of insulin resistance syndrome (11,12,30). We also have found that hyperinsulinemia at baseline predicts incident dyslipidemia and hypertension 4 years later in the KIHD population (33).

Our data indicate that weight gain contributes to metabolic and hemodynamic abnormalities before clinical manifestation of IHD. Weight gain predicted the likelihood of insulin resistance syndrome in middle age equally well in men with and without prevalent IHD at baseline. Indeed, risk of having insulin resistance syndrome according to weight-gain categories was similar in men with and without IHD. Prevalence and incidence of CVD are higher in individuals with multiple metabolic disorders compared with those with one or fewer abnormalities (10). Thus, interventions to reduce weight and prevent further weight gain among men already exhibiting

insulin resistance syndrome and before clinical IHD could contribute to a decrease in clinically significant CVD and its associated costs and consequences.

One limitation of this study is the use of self-reported weight at age 20. Measured weight at both times would have been ideal because self-reported weight tends to be biased toward underreporting (34), particularly among overweight individuals (35). However, several studies indicate that subjects' reports of their weight during young adulthood are reasonably accurate and can be reliably used in epidemiological investigations when measured weight is not available (35–37). Lissner et al. (38) found that weight during young adulthood may have important implications for health in later life and may be captured by using weight at age 20. Also, a recent report from the Atherosclerosis Risk in Communities study (39) found that weight change, calculated as the difference between self-reported weight at age 25 and measured weight some 30 years later, was associated with carotid artery wall thickness among men and white women. In the present study, we were able to assess the association between self-report of current weight and measured weight among a subset of our participants. At baseline, current smokers ($n = 608$) completed the Prochaska smoking questionnaire, which includes a question on current weight. Self-reported weight and measured weight were highly correlated in this sample ($r = 0.95$; $P < 0.0001$). Within the categories of percent weight change, this correlation ranged from 0.83 to 0.96, indicating that self-reports of current weight were no more or less accurate based on the amount of weight gained from young to middle adulthood.

Another limitation is the lack of information on timing or pattern of weight gain among our participants. These patterns may be related to health outcomes in an important way (5,27,40,41). Prevalence of overweight increases with advancing age (42), suggesting that weight gain in adulthood occurs gradually over time. Unfortunately, we do not know if the weight gain experienced by our participants was gradual from age 20 or if most of their weight increase occurred closer to the baseline examination, although it seems unlikely that these men experienced dramatic weight gains immediately before the baseline exams. We also were not able to examine the impact of diet or physical activity from young to middle adulthood on weight gain and development of insulin resistance syndrome. We do know

that most of our participants were in the Finnish Army at age 20 during the post World War II years, when food was less plentiful, and it is likely that they were more physically active as younger men than in later years as they approached middle age. Also, as these men aged, the standard diet in Finland became higher in fat and calories (43). Almost all of the men started out at approximately the same BMI (22.6 kg/m^2 for noncases and 22.7 kg/m^2 for cases at age 20). The men who gained the most weight—presumably caused by increased dietary energy intake, decreased physical activity, genetic predisposition, or some combination of the three—were at the greatest risk of developing insulin resistance syndrome.

Findings from this study of middle-aged white men may not be generalizable to non-white populations or to women; however, results are consistent with a recent study that found an increased risk of CVD deaths among women who gained weight from age 18 to middle age (44). Our findings support the evidence that hypertension, diabetes, and dyslipidemia are biological consequences of obesity (45–47) and confirm that insulin resistance syndrome can occur in nonobese individuals (13).

In summary, this study adds to the extant literature identifying deleterious effects of weight gain and obesity from young adulthood to middle age. Public health strategies must be targeted at reducing high-calorie diets and increasing physical activity if they are to have any chance of reversing recent trends in obesity (42) and avoiding associated adverse health consequences. Additionally, these findings point to the need to identify individuals early, before significant weight gain and before conditions develop that are difficult to manage and that may lead to overt diseases such as CVD and type 2 diabetes.

Acknowledgments— This study was supported by grant HL44199 from the National Heart, Lung, and Blood Institute and by grants from the Academy of Finland and the Finnish Ministry of Education. T.A.L. was supported by grants from the Yrjö Jahnsson Foundation and the Juho Vainio Foundation, and J.T.S. was an Academy Professor of the Academy of Finland.

References

1. Hanson RL, Narayan KMV, McCance DR, Pettitt DJ, Jacobsson LTH, Bennett PH, Knowler WC: Rate of weight gain, weight fluctuation, and incidence of NIDDM. *Diabetes* 44:261–266, 1995

2. Colditz GA, Willett WC, Rotnitzky A, Manson JE: Weight gain as a risk factor for clinical diabetes mellitus in women. *Ann Int Med* 122:481–486, 1995
3. Wing RR, Jeffery RW, Hellerstedt WL: A prospective study of weight cycling on cardiovascular risk factors. *Arch Intern Med* 155:1416–1422, 1995
4. Horton ES: Exercise and decreased risk of NIDDM. *N Engl J Med* 325:196–198, 1991
5. Walker M, Wannamethee G, Whincup PH, Shaper AG: Weight change and risk of heart attack in middle-aged British men. *Int J Epidemiol* 24:694–703, 1996
6. Ford ES, Williamson DF, Liu S: Weight change and diabetes incidence: findings from a national cohort of US adults. *Am J Epidemiol* 146:214–222, 1997
7. Lee IM, Paffenbarger RS: Change in body weight and longevity. *JAMA* 268:2045–2049, 1992
8. Kannel WB, D'Agostino RB, Cobb JL: Effect of weight on cardiovascular disease. *Am J Clin Nutr* 63 (Suppl. 3):419S–422S, 1996
9. Kaplan NM: Primary hypertension: pathogenesis. In *Clinical Hypertension* 7th ed. Baltimore, MD, Williams & Wilkins, 1998, p. 41–99
10. Vague P, Raccach D: The syndrome of insulin resistance. *Horm Res* 38:28–32, 1992
11. Kaplan NM: Insulin resistance syndrome: two too many. *Am J Cardiol* 69:1643–1644, 1992
12. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP: Prospective analysis of the insulin-resistance syndrome (syndrome X). *Diabetes* 41:715–722, 1992
13. Reaven GM: Role of insulin resistance in human disease (syndrome X): an expanded definition. *Ann Rev Med* 44:121–131, 1993
14. Yalow RJ, Blick IM, Roth J, Berson SA: Plasma insulin and growth hormone in obesity and diabetes. *Ann N Y Acad Sci* 131:357–373, 1965
15. Salonen JT: Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. *Ann Clin Res* 20:46–50, 1988
16. Lakka TA, Salonen JT: Intra-person variability of various physical activity assessments in the Kuopio Ischaemic Heart Disease Risk Factor Study. *Int J Epidemiol* 21:467–472, 1992
17. Salonen JT, Salonen R, Seppänen K, Rauramaa R, Tuomilehto J: HDL, HDL₂, and HDL₃ cholesterol subfractions and the risk of acute myocardial infarction: a prospective population study in eastern Finnish men. *Circulation* 84:129–139, 1991
18. Joint National Committee: The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI). *Arch Intern Med* 157:2413–2439, 1997

19. World Health Organization: *Report of a WHO Expert Committee on Arterial Hypertension* Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
20. Pyörälä K, De Backer G, Graham L, Poole-Wilson P, Wood D: Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. *Eur Heart J*15:1300-1331, 1994
21. World Health Organization: *Report of a WHO Expert Committee on Diabetes Mellitus* Geneva, World Health Org., 1978 (Tech. Rep. Ser., no. 628)
22. Lakka T, Venalainen JM, Rauramaa R, Salonen R, Tuomilehto J, Salonen JT: Conditioning leisure time physical activity and cardiorespiratory fitness as predictors of acute myocardial infarction in eastern Finnish men. *N Engl J Med*330:1549-1554, 1994
23. Lynch J, Helmrich SP, Lakka TA, Kaplan GA, Cohen RD, Salonen R, Salonen JT: Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle-aged men. *Arch Intern Med*156:1307-1314, 1996
24. Maclure M, Greenland S: Tests of trend and dose response: misinterpretations and alternatives. *Am J Epidemiol*135:96-104, 1992
25. Laakso M: How good a marker is insulin level for insulin resistance? *Am J Epidemiol*137:959-965, 1993
26. Rose GA, Blackburn H, Gillum RF, Prineas RJ: *Cardiovascular Survey Methods* Geneva, World Health Org., 1982
27. Sims EAH, Danforth E Jr, Horton ES, Bray GA, Glennon GA, Salans LB: Endocrine and metabolic effects of experimental obesity in man. *Recent Prog Horm Res*29:457-496, 1973
28. Modan M, Karasik A, Halkin H, Fuchs Z, Shitrit A, Modan B: Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non-insulin-dependent) diabetes and on insulin response: the Israel study of glucose intolerance, obesity and hypertension. *Diabetologia*29:82-89, 1986
29. Horton ES: Exercise and decreased risk of NIDDM. *N Engl J Med*325:196-198, 1991
30. Ferrannini E, Haffner SM, Mitchell BD, Stern MP: Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. *Diabetologia*34:416-422, 1991
31. Reaven GM: Role of insulin resistance in human disease. *Diabetes*37:1595-1607, 1988
32. Edwards KL, Newman B, Mayer E, Selby JV, Krauss RM, Austin MA: Heritability of factors of the insulin resistance syndrome in women twins. *Genet Epidemiol*4:241-253, 1997
33. Salonen JT, Lakka TA, Lakka H-M, Valkonen V-P, Everson SA, Kaplan GA: Hyperinsulinemia is associated with the incidence of hypertension and dyslipidemia in middle-aged men. *Diabetes*47:270-275, 1998
34. Hauck FR, White L, Cao G, Woolf N, Strauss K: Inaccuracy of self-reported weights and heights among American Indian adolescents. *Ann Epidemiol*6:386-392, 1995
35. Stevens J, Keil J, Waid R, Gazes PC: Accuracy of current, 4-year, and 28-year self-reported body weight in an elderly population. *Am J Epidemiol*132:1156-1163, 1990
36. Stunkard AJ, Albaum JM: The accuracy of self-reported weights. *Am J Clin Nutr*34:1593-1599, 1981
37. Willett W, Stampfer M, Bain C, Lipnick R, Speizer FE, Rosner B, Cramer D, Hennekens CH: Cigarette smoking, relative weight, and menopause. *Am J Epidemiol*117:651-658, 1983
38. Lissner L, Andres R, Muller DC, Shimokata H: Body weight variability in men: metabolic rate, health and longevity. *Int J Obesity*14:373-383, 1990
39. Stevens J, Tyroler HA, Cai J, Paton CC, Folsom AR, Tell GS, Schreiner PJ, Chambless LE: Body weight change and carotid artery wall thickness: the Atherosclerosis Risk in Communities (ARIC) Study. *Am J Epidemiol*147:563-573, 1998
40. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr: Physical activity and reduced occurrence of non-insulin dependent diabetes mellitus. *N Engl J Med*325:147-152, 1991
41. Borkan GA, Sparrow D, Wisniewski C, Vokonas PS: Body weight and coronary disease risk: patterns of risk factor change associated with long-term weight change: the Normative Aging Study. *Am J Epidemiol*124:410-419, 1986
42. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL: Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. *JAMA*272:205-211, 1994
43. Pietinen P, Vartiainen E, Seppanen R, Aro A, Puska P: Changes in diet in Finland from 1972 to 1992: impact on coronary heart disease risk. *Prev Med*25:243-250, 1996
44. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Junter DJ, Hankinson SE, Hennekens CH, Speizer FE: Body weight and mortality among women. *N Engl J Med*333:677-685, 1995
45. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, Willett WC: Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. *Am J Epidemiol*12:1117-1127, 1995
46. Mann GV: The influence of obesity on health (first of two parts). *N Engl J Med*291:178-185, 1974
47. Mann GV: The influence of obesity on health (second of two parts). *N Engl J Med*291:226-232, 1974